Navigation Links
Aida Announces New Anti-Cancer Drug Under Development
Date:4/18/2008

SANTA MONICA, Calif., April 18 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) (hereinafter referred to as "Aida") today announced that it is developing a potential cancer drug that seeks to trigger cell death in certain types of cancer. Vasostatin-Apo2L, a pre-clinical product being developed by Aida's Shanghai Qiaer subsidiary, is a recombinant fusion protein that integrates the function of extracted fragments of Vasostatin, an inhibitor of angiogenesis and tumor growth, with the function of Rh-Apo2L, which induces the apoptosis of cancer cells. It has shown positive results in the lab. Aida's researchers believe that the integration of Vasostatin-Apo2L will have higher efficacy in certain cancer treatments than currently prescribed methods.

Aida estimates that Vasostatin will have a target market of 80,000-100,000 patients per year after it is successfully brought to market and this will contribute significantly to Aida's revenue.

Vasostatin-Apo2L is developed by the same research team that created Rh-Apo2L. Rh-Apo2L has successfully completed its Phase 2 clinical testing and is going to file application with the PRC government's State Food and Drug Administration to start the Phase III trials. The development of Vasostatin-Apo2L will benefit strongly from the experience garnered in the research, manufacturing and distribution of Rh-Apo2L.

About Aida Pharmaceuticals

Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. Aida Pharmaceuticals, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP certified in China and ISO90
'/>"/>

SOURCE Aida Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...THOUSAND OAKS, Calif., Nov. 21 /PRNewswire-FirstCa...at the European Committee for Medicinal,Products ... recommending,marketing authorisation for Nplate(...e CHMP recommends Nplate for adult chronic immune ...ectomised patients who are refractory to,other tr...
(Date:11/21/2008)...CLINTON, N.J., Nov. 21 Ikaria Hold...Private Company of the Year by the New Jersey Tech...rganization that provides business support, networ...echnology companies and their leaders. Ikaria earn...adership and unique product/service provision. , ...
(Date:11/20/2008)...WASHINGTON, Nov. 20 The...& Gender Equity: , , WHAT: World AIDS..., Tuesday, November 25, 2008 , 11:00 a.m. EST...ongly encouraged: https://cc.readytalk.com/r/1xe4...ns outpacing the number of people newly put on tre...
(Date:11/20/2008)... , , , , PHILADELPHIA, Nov. 20 /PRN...) today announced that the United States Food and ...oval for PROMACTA(R) (eltrombopag) for the treatme...mune (idiopathic) thrombocytopenic purpura (ITP) w...roids, immunoglobulins or splenectomy. The approva...
Breaking Medicine Technology:Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 2Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 3Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 4Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 5Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 6Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 7Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 8Ikaria(R) Named Private Company of the Year by New Jersey Technology Council 2Faith and Civil Society Leaders Call for Truth and Leadership in U.S. HIV Prevention Efforts 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Corgenix Signs Technology Licensing Agreement With Japanese Government 4049 1Corgenix Signs Technology Licensing Agreement With Japanese Government 4049 2Do bacterial combinations result in enhanced cytokine production 3F No 21 14573 1Do bacterial combinations result in enhanced cytokine production 3F No 21 14573 2Does stress damage the brain 3F 14568 1Does stress damage the brain 3F 14568 2Safe at Any Age 3A Octogenarians Do As Well as Younger Patients With Interventional Radiology Arterial Procedures 14563 1Safe at Any Age 3A Octogenarians Do As Well as Younger Patients With Interventional Radiology Arterial Procedures 14563 2Safe at Any Age 3A Octogenarians Do As Well as Younger Patients With Interventional Radiology Arterial Procedures 14563 3
...rvard Medical School ,Contributing Editor , ,... per year, breast cancer undoubtedly qualifies as ...ently, efforts to develop early detection methods ...gress. This is particularly true at the molecular...ve translated into new diagnostic tests and target...
...ibuting Editor ,Harvard Medical School ,The...two of the most important classes of fungi in clin...onment, and hospitals are no exception. Perhaps t...a ) and pulmonary hypersensitivity ( Aspergillus )...tions, but by virtue of intact physical barriers a...
Other Medicine Technology:Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy 2Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy 3New Assays to Detect Disseminated Fungal Infections 2New Assays to Detect Disseminated Fungal Infections 3
(Date:11/21/2008).../ -- The Generic,Pharmaceutical Association (GPhA...A President and CEO Kathleen Jaeger regarding the ...rging Health Care Competition and Consumer Issues....ng this roundtable demonstrates the,growing momen...safe and,affordable biogenerics sooner rather tha...
(Date:11/21/2008)...e University of Texas M. D. Anderson Cancer Cent...to eradicate breast cancer in Panama through the P...h of the Americas today at an event with Laura Bus... Fernandez de Torrijos, the First Lady of Panama. ...e are the U.S. Department of State and Susan G. Ko...
(Date:11/21/2008).../ -- U.S. News & World Report and the National...eChoice(R) HealthPlan of South Carolina in the top...ed in U.S. News & World Report,s issue this we...the nation,s best health plans based on clinical q... scores. NCQA and U.S. News & World Report ran...
(Date:11/21/2008)...ic damage that can lead to disease , , F...ications for treating attention-deficit hyperactiv...nked to an increased risk for developing cancer, a...rs at Duke University Medical Center and the Natio...that reported biomarkers associated with an increa...
Breaking Medicine News(10 mins):Health News:GPhA Statement on FTC Roundtable on Biogenerics 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 3Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2Health News:ADHD Medications Don't Pose Cancer Risk 2
...d that though they do not develop zits, the do hav...re able to differentiate the cells// in the sebace... The research examines how a sebaceous gland is fo...he August 11 issue of Cell, Elaine Fuchs, a Howard...
...more than 345 youngsters suffered from type1diabet...ases for the county, Dr Ian Gibson,// a former cha...tee, said in an interview that inbreeding might be...ontroversy. He said: "I would imagine it is linke...
...vitation into the world of drugs and the beginnin...to the vortex of drugs. Living up to peer expectat...g' and be the life of every party, drives many to...wns, drugs begin to call the shots and many lives ...
...Thursday edition of a local newspaper, Vietnam New...ndoms for the first time in Vietnam.// As a measu...nd distribution of condoms under a law on HIV/AIDS... 2007. Presently, condom sales and distribution ar...
Other Medicine News:Health News:'Blimp1' Gene Linked To Oily Skin 2Health News:Bitter Pill: Thrills That Kill 2Health News:Bitter Pill: Thrills That Kill 3
...ple, effective screening test which is used to ide...d sugar) levels which are often a warning sign of ...h requires a single drop of blood obtained from a ...n in clinical trials to be 94 to 99.95 percent acc...
The Lifestream Plus Cholesterol Monitor provides you with a comprehensive tool to help you monitor your cholesterol as part of your wellness program.
CardioChek™ PA Portable Whole Blood Test System
The Accustrip Strep A(ll) Test is a lateral flow, one-step immunoassay for the rapid, qualitative detection of Group A Streptococcal antigen from throat swabs. The test is intended for use as an aid
Medicine Products: